Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen is a component of several quadrivalent and bivalent vaccines designed to prevent invasive disease caused by Neisseria meningitidis serogroup C. This vaccine antigen consists of the purified capsular polysaccharide from Neisseria meningitidis serogroup C covalently linked (conjugated) to tetanus toxoid protein. The conjugation enhances immunogenicity, especially in infants and young children, by inducing a T-cell dependent immune response that leads to long-lasting immunity and immunological memory. These vaccines are primarily indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups including C[3][6][8]. Major products containing this antigen include MenQuadfi (Sanofi), Nimenrix (Pfizer), and Penbraya (Pfizer). The primary indication is prevention of invasive meningococcal disease.
- Brand names
- MenQuadfiNimenrixPenbraya
- Other names
- Nimenrix component neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
02
Targets
TT (Tetanus toxoid)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen.